First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

Background E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safety, tolerability, pharmacokinetics, pharmacodynamic...

Полное описание

Библиографические подробности

Главные авторы:	Aurélien Marabelle, Aung Naing, Funda Meric-Bernstam, Xingfeng Bao, Andrea Varga, David S Hong, Aparna Parikh, Geoffrey I Shapiro, Özlem Ataman, Larisa Reyderman, Terri A Binder, Min Ren, Mingjie Liu, Satish Dayal, Amy Y Siu, Pallavi Sachdev, Lucy Xu, Vijay Bhagawati-Prasad, Ilian Tchakov, Chean Eng Ooi
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMJ Publishing Group 2020-05-01
Серии:	Journal for ImmunoTherapy of Cancer
Online-ссылка:	https://jitc.bmj.com/content/8/1/e000222.full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!